Future implications of EU HTA and how Next Gen get involved

Interview with Katrin Kupas and Dr. Arthur Allignol All statisticians in the Pharmaceutical Industry will be impacted by the new EU HTA regulation. Activities around HTA submissions will happen earlier than currently, in parallel to the regulatory approval process for marketing authorization. There will be an increased scope of evidence for the joint clinical assessment to fulfill the needs of all EU member states, and so there will be a large package of statistical analyses that need to be provided in addition to the submission to the regulatory bodies. This will redefine how you, as a statistician, work, and with whom you need to collaborate. Both HTA and clinical development statisticians will need to join forces to define the value story for the complete lifecycle of the drug. HTA specific analyses will need to be planned in parallel with clinical development. In this episode, we will discuss the future skill sets that statisticians in the pharmaceutical industry need to adopt with the new EU HTA regulation being applied in 2025 already.